IL2 and autoimmune disease: These results represent the first evidence, based on published data, supporting the notion that Ld-IL2 therapy in autoimmune diseases can benefit patients by reducing the risk of infection, a feature outcompeting conventional immunosuppressive therapy (Fig 6).